Track Fox04‑DRI in Peptimes™
FOXO4-DRI is an experimental peptide designed to disrupt the interaction between the FOXO4 and p53 proteins in senescent cells. It was described in a 2017 cell and mouse study. (Source: PubMed.)
Is Fox04-DRI FDA-approved?
No. FOXO4-DRI isn't FDA-approved, and Drugs@FDA lists no application with it as an active ingredient.
Fox04-DRI
Also: FOXO4-DRI, FOXO4 D-retro-inverso peptide
- Status label in the Peptimes Library
- Not FDA-Approved
- Routes in Peptimes
- SubcutaneousIntramuscularOralSublingualNasalTopicalOther
- Updated
- 1 Nov 2026
US regulatory status
What studies have looked at
Each point says who or what was studied and what the study reported, with its source and the date we checked it. These are findings from the sources cited, not advice or a promise of any result.
- In animals or the lab
In senescent cells, the peptide caused p53 to leave the nucleus and triggered cell death. In fast-ageing and naturally aged mice, it restored fitness, fur density and kidney function.
Source: PMID 28340339, checked 1 Nov 2026
How to track it in Peptimes
Add Fox04-DRI in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Not FDA-Approved”.
- Routes: the app lets you record whichever route you used; none is established. Its routes are subcutaneous, intramuscular, oral, sublingual, nasal, topical and Other.
- Logging: the amount you took, the route and how you feel.
- Injection sites: subcutaneous and intramuscular doses record the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next. Other routes skip this step.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell FOXO4-DRI or any other compound.
More sources
- NIH, ClinicalTrials.gov, search for FOXO4-DRI, checked 1 Nov 2026: no registered study.